Skip to main content
SpringerLink
Log in
Book cover

Peritoneal Tumors and Metastases pp 189–201Cite as

Indication of CRS and HIPEC in Gastric Cancer-Related Peritoneal Metastasis

  • Chapter
  • First Online:

  • 497 Accesses

Abstract

The ratio of peritoneal metastasis in advanced gastric cancer is approximately 40%. Patients with peritoneal metastasis of gastric cancer have limited treatment options and a poor prognosis of only 3 months survival without treatment. Systemic chemotherapy, as the first line treatment option according to national and international guidelines, improves survival up to 7–11 months. During the last two decades, the concept of cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy has been established and proved survival benefit in selected patients with median survival up to >15 months. Factors such as a low Peritoneal Cancer Index (<6) and the completeness of cytoreduction are the most important predictive factors for survival after surgery, but also more recently biologic and pathologic markers have been discovered and are under validation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, The P Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Grain WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, YES P, Sasson AR, Scott WJ, Strong VE, Varghese TK Jr, Warren G, Washington MK, Willett C, Wright CD, NR MM, Sundar H. Gastric cancer, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2013;11:531–46.

    Article  CAS  Google Scholar 

  2. Aurello P, Petrucciani N, Giulitti D, Campanella L, D'Angelo F, Ramacciato G. Pulmonary metastases from gastric cancer: is there any indication for lung metastasectomy? A systematic review. Med Oncol. 2016;33:9.

    Article  PubMed  CAS  Google Scholar 

  3. Bang YJ, Van CE, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, pen-KOV E, Hill J, Lehle M, Ruschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687–97.

    Article  CAS  PubMed  Google Scholar 

  4. Boerner T, Graichen A, Jeiter T, Zemann F, Renner P, Marz L, Soeder Y, Schlitt HJ, Piso P, Dahlke MH. CRS-HIPEC prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23:3972–7.

    Article  CAS  PubMed  Google Scholar 

  5. Burke EC, Karpeh MS Jr, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann Surg Oncol. 1998;5:411–5.

    Article  CAS  PubMed  Google Scholar 

  6. The Cancer Genome Atlas Research Network, bass A, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.

    Article  CAS  Google Scholar 

  7. Cao L, Selby LV, Hu X, Zhang Y, Janjigian YY, Tang L, Coit DG, Brennan MF, Strong VE. Risk factors for recurrence in T1-2N0 gastric cancer in the United States, China. J Surg Oncol. 2016;113:745–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Chang JS, Kim KH, Keum KC, Noh SH, Lim JS, Kim HS, Rha SY, Lee YC, Hyung WJ, Koom WS. Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: implications for neoadjuvant therapy consideration. J Surg Oncol. 2016;114:859–64.

    Article  PubMed  Google Scholar 

  9. Chang-Yun L, Yonemura Y, Ishibashi H, Sako S, Tsukiyama G, Kitai T, Matsuki N. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in peritoneal carcinomatosis. Gan To Kagaku Ryoho. 2011;38:2060–4.

    PubMed  Google Scholar 

  10. Cui J, Yin Y, Ma Q, Wang G, Olman V, Zhang Y, Chou WC, Hong CS, Zhang C, Cao S, Mao X, Li Y, Qin S, Zhao S, Jiang J, Hastings P, Li FXY. Comprehensive characterization of the genomic alterations in human gastric cancer. Int J Cancer. 2015;137:86–95.

    Article  CAS  PubMed  Google Scholar 

  11. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Magic TP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  CAS  PubMed  Google Scholar 

  12. Dewey WC. Interaction of heat with radiation chemotherapy. Cancer Res. 1984;44:4714–20.

    Google Scholar 

  13. Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J, Schumberger M, Sigal R, Elias D. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Celiac Imaging. 2008;33:87–93.

    Google Scholar 

  14. Ebinger SM, Warschkow R, Tarantino I, Smith BM, Guller U, Schiesser M. Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer. 2016;19:723–34.

    Article  PubMed  Google Scholar 

  15. Esaki Y, Hirayama R, Hirokawa K. A comparison of patterns of metastasis in gastric cancer by histologic type and age. Cancer. 1990;65:2086–90.

    Article  CAS  PubMed  Google Scholar 

  16. Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Shen P, Stewart JH, Sugarbaker PH, Barone RM, Hoefer R, Morris DL, Sardi A, Sticca RP. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102:565–70.

    Article  CAS  PubMed  Google Scholar 

  17. Facchiano E, Risio D, Kianmanesh R, Msika S. Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. Ann Surg Oncol. 2012;19:2946–50.

    Article  PubMed  Google Scholar 

  18. Feingold PL, Kwong ML, Davis JL, Rudloff U. Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: a systematic review. J Surg Oncol. 2016;115:192–201.

    Article  PubMed  Google Scholar 

  19. Ford HE, Marshall A, Bridgewater YES, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA. Doce taxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomized controlled trial. Lancet Oncol. 2014;15:78–86.

    Article  CAS  PubMed  Google Scholar 

  20. Fujimoto S, Shrestha RD, Kokubun M, et al. Intra peritoneal perfusion Hyperthermic combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg. 1988;208:36–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshi Kawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (RACING): a phase 3, randomized controlled trial. Lancet Oncol. 2016;17:309–18.

    Article  CAS  PubMed  Google Scholar 

  22. Garofalo A, Valle M. Laparoscopy in the management of peritoneal carcinomatosis. Cancer J. 2009;15:190–5.

    Article  PubMed  Google Scholar 

  23. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692–8.

    Article  PubMed  Google Scholar 

  24. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients Treated by cyto reductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010a;17:2370–7.

    Article  PubMed  Google Scholar 

  25. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010b;116:5608–18.

    Article  PubMed  Google Scholar 

  26. Goere D, Grass Chaput N, Auperin A, Flament C, Mariette C, Glehen O, Zitvogel L, Elias D. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer. 2014;14:148. https://doi.org/10.1186/1471-2407-14-148.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hall EJ, Brenner DJ. The radiobiology of radiosurgery: rational for different treatment regimes for AVMs and malignancies [see comments]. Int J Radiat Oncol Biol Phys. 1993;25:381–5.

    Article  CAS  PubMed  Google Scholar 

  28. Hultman B, Lind P, Glimelius B, Sundbom M, Nygren P, Haglund U, Mahteme H. Phase II study of patients with peritoneal carcinomatosis from gastric Treated cancer with preoperative systemic chemotherapy therapy Followed by peritonectomy and intraperitoneal chemotherapy. Acta Oncol. 2013;52:824–30.

    Article  PubMed  Google Scholar 

  29. Jacquet P, Sugar Baker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

    Article  CAS  PubMed  Google Scholar 

  30. Jacquet P, Jelinek JS, Steve MA, Sugar Baker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72:1631–6.

    Article  CAS  PubMed  Google Scholar 

  31. Jeong O, Park YK, Choi WY, Ryu SY. Prognostic significance of non-curative gastrectomy for gastric carcinoma incurable. Ann Surg Oncol. 2014a;21:2587–93.

    Article  PubMed  Google Scholar 

  32. Jeong O, Park YK, Choi WY, Ryu SY. Prognostic significance of non-curative gastrectomy for gastric carcinoma incurable. Ann Surg Oncol. 2014b;21:2587–93.

    Article  PubMed  Google Scholar 

  33. Kanda M, Mizuno A, Fujii T, Shimoyama Y, Yamada S, Tanaka C, Kobayashi D, Koike M, Iwata N, Niwa Y, Hayashi M, Takami H, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y. Tumor infiltrative pattern predicts sites of recurrence after curative gastrectomy for stages 2 and 3 gastric cancer. Ann Surg Oncol. 2016;23:1934–40.

    Article  PubMed  Google Scholar 

  34. Kim KW, Chow O, Parikh K, Blank S, Jibara G, Kadri H, Labow DM, Hiotis SP. Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. Am J Surg. 2014;207:78–83.

    Article  PubMed  Google Scholar 

  35. Klumpp B, Schwenzer NF, Gatidis S, Koenig Rainer I, Koenig Rainer A, Beckert S, Mueller M, Claussen CD, Pfannenberg C. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal Chemotherapy using F-18-FDG-PET/CT. Rofo. 2014;186:359–66.

    Article  CAS  PubMed  Google Scholar 

  36. Kong X, Wang JL, Chen HM, Fang JY. Comparison of the clinicopathological characteristics of young and elderly patients with gastric carcinoma: a meta-analy sis. J Surg Oncol. 2012;106:346–52.

    Article  PubMed  Google Scholar 

  37. Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, Rowsell C, Coburn NG. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;(15 Suppl 1):27–37.

    Google Scholar 

  38. Liu X, Cai H, Sheng W, Wang Y. Long-term results and prognostic factors of gastric cancer patients with peritoneal carcinomatosis micro scopic. PLoS One. 2012;7:e37284.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Low RN, Barone RM, Lee MJ. Surveillance MR imaging is superior to serum tumor markers for Detecting early tumor recurrence in patients with appendiceal cancer Treated with surgical cytoreduction and HIPEC. Ann Surg Oncol. 2013;20:1074–81.

    Article  PubMed  Google Scholar 

  40. Mirza A, Pritchard S, Welch I. The postoperative component of MAGIC chemotherapy is associated with improved prognosis Following surgical resection in gastric and gastroesophageal junction adenocar cinomas. Int J Surg Oncol. 2013. 2013: doi 781,742th:10.1155 / 2013/781742.

    Google Scholar 

  41. Moehler M, Baltin CT, Ebert M, Fischbach W, Gockel I, Grenacher L, Holscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer HJ, Palmqvist A, Distaff C, Shoe Maker C, Steel M, Stuschke M, Vieth M, Wittekind C, Wagner D, Monig SP. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 2015;18:550–63.

    Article  PubMed  Google Scholar 

  42. Nunez MF, Sardi A, Jimenez W, Nieroda C, Sittig M, Mac Donald R, Aydin N, Milovanov V, Gushchin V. Port-site metastases is an independent prognostic factor in patients with peritoneal carcinomatosis. Ann Surg Oncol. 2015;22:1267–73.

    Article  PubMed  Google Scholar 

  43. Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst. 2013;105:1600–7.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, Usuki H, Maeta H. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 2002;235:86–91.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Ott K, Vogelsang H, Mueller J, Becker K, Muller M, Fink U, Siewert JR, Hofler H, Keller G. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy therapy in gastric carcinoma. Clin Cancer Res. 2003;9:2307–15.

    CAS  PubMed  Google Scholar 

  46. Pasquali S, Yim G, Vohra RS, Mocellin S, Nyanhongo D, Marriott P, Go JI, Griffiths EA. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for esophageal carcinoma resectable: a network meta-analysis. Ann Surg. 2016;265:481–91.

    Article  Google Scholar 

  47. Rau B, Brandl A, Piso P, Pelz J, Busch P, Demtroder C, Schule S, Schlitt HJ, Roitman M, Tepel J, Sulkowski U, Uzunoglu F, Hunerbein M, Horbelt R, Strohlein M, Beckert S, Konigsrainer I, Konigsrainer A. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23(1):11–22.

    Article  PubMed  Google Scholar 

  48. Rau B, Brandl A, Thuss-Patience P, Bergner F, Raue W, Arnold A, Horst D, Pratschke J, Biebl M. The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis. Gastric Cancer. 2019;22(6):1226–37.

    Article  CAS  PubMed  Google Scholar 

  49. RKI. Prevalence of cancers in Germany: Robert Koch Institute; 2016. p. 1–181.

    Google Scholar 

  50. Seyfried F, of Rahden bra, Miras AD, Gasser M, Maeder U, Kunzmann V, Germer CT, Fur J, Kerscher AG. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin – a longitudinally experience from a prospectively collected database of 1,108 patients. BMC Cancer. 2015;15 https://doi.org/10.1186/s12885-015-1081-8.73-1081.

  51. Spratt JS, Adcock RA, Sherrill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Res. 1980;40:253–5.

    CAS  PubMed  Google Scholar 

  52. Stewart B, Wild CP. International Agency for Research on Cancer. In: Stew B, Wild CP (eds) IARC Nonserial Publication; 2014.

    Google Scholar 

  53. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254–61.

    Article  CAS  PubMed  Google Scholar 

  54. Sugarbaker PH, Jablonski KA. Prognostic features of colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreduc tive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE, Impact P. Rationale for integra ting early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16:83–97.

    CAS  PubMed  Google Scholar 

  56. Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, Zhou B, Xu H. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13(577) https://doi.org/10.1186/1471-2407-13-577.577-13.

  57. Thomassen I, Bernards N, van Gestel YR, Creemers GJ, Jacobs EM, Lemmens VE, de Hingh IH. Chemotherapy as a palliative treatment for peritoneal carcinomatosis of gastric origin. Acta Oncol. 2014a;53:429–32.

    Article  PubMed  Google Scholar 

  58. Thomassen I, van Gestel YR, Aalbers AG, van Oudheusden TR, Wegdam YES, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis is less frequently diagnosed during laparoscopic surgery compared to open surgery in patients with colorectal cancer. Eur J Surg Oncol. 2014b;40:511–4.

    Article  CAS  PubMed  Google Scholar 

  59. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomized phase III study of the Arbeitsgemeinschaft Medical oncology (AIO). Eur J Cancer. 2011;47:2306–14.

    Article  CAS  PubMed  Google Scholar 

  60. Valle SJ, Alzahrani NA, Alzahrani SE, Liauw W, Morris DL. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg. 2015;23:176–80.

    Article  CAS  PubMed  Google Scholar 

  61. Wu X, Li Z, Li Z, Jia Y, Shan F, Ji X, Bu Z, Zhang L, Wu A, Ji J. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. J Surg Oncol. 2015;111:840–7.

    Article  PubMed  Google Scholar 

  62. Xie D, Liu L, Osaiweran H, Yu C, Sheng F, Gao C, Hu J, Gong J. Detection and characterization of metastatic cancer cells in the mesogastrium of gastric cancer patients. PLoS One. 2015;10:e0142970.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Yan TD, Morris DL, Shigeki K, Dario B, Marcello D. Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement. J Surg Oncol. 2008;98:224–7.

    Article  PubMed  Google Scholar 

  64. Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2010;2:109–16.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Yarema RR, Ohorchak MA, Zubarev GP, Mylyan YP, Oliynyk YY, Zubarev MG, Gyrya PI, Kovalchuk YJ, Safiyan VI, Fetsych TG. Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: results of a single-center retrospective study. Int J Hyperth. 2014;30:159–65.

    Article  CAS  Google Scholar 

  66. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for RESEC-table gastroesophageal adenocarcinoma: to FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.

    Article  CAS  PubMed  Google Scholar 

  67. Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, Ichinose M, Miura M, Li Y. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastro intest Oncol. 2010;2:85–97.

    Article  Google Scholar 

  68. Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, Li Y. Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012, 2012. 148,420th: 10.1155 / 2012/148420.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität of Berlin, Berlin, Germany

    Beate Rau

  2. Department of Surgery, Campus Virchow-Klinikum and Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Eva Pachmayr

  3. Head of Upper GI Oncology, Charité-University Medicine Berlin, Berlin, Germany

    Peter Thuss-Patience

  4. Medical Clinic for Hematology, Oncology and Tumor-Immunology, Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Peter Thuss-Patience

  5. Department of Surgical Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

    Pankaj Kumar Garg

  6. Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, Lyon, France

    Olivier Glehen

  7. Digestive Unit, Champalimaud Foundation, Lisbon, Portugal

    Andreas Brandl

Authors
  1. Beate Rau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eva Pachmayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Thuss-Patience
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pankaj Kumar Garg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olivier Glehen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andreas Brandl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beate Rau .

Editor information

Editors and Affiliations

  1. Department of Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität of Berlin, Berlin, Germany

    Beate Rau

  2. Department of General, Visceral and Transplant Surgery, University Hospital of Tübingen, Comprehensive Cancer Center, Tübingen, Germany

    Alfred Königsrainer

  3. Basingstoke and North Hampshire Hospital, Peritoneal Malignancy Institute, Basingstoke, UK

    Faheez Mohamed

  4. Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, DC, USA

    Paul H. Sugarbaker

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rau, B., Pachmayr, E., Thuss-Patience, P., Garg, P.K., Glehen, O., Brandl, A. (2021). Indication of CRS and HIPEC in Gastric Cancer-Related Peritoneal Metastasis. In: Rau, B., Königsrainer, A., Mohamed, F., Sugarbaker, P.H. (eds) Peritoneal Tumors and Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-62640-2_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62640-2_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62639-6

  • Online ISBN: 978-3-030-62640-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation